tiprankstipranks
Autonomix Medical, Inc. (AMIX)
:AMIX
US Market

Autonomix Medical, Inc. (AMIX) AI Stock Analysis

Compare
97 Followers

Top Page

AM

Autonomix Medical, Inc.

(NASDAQ:AMIX)

37Underperform
Autonomix Medical, Inc. faces significant financial challenges, primarily due to its inability to generate revenue and positive cash flow. The technical analysis indicates bearish momentum, and the valuation suggests potential overvaluation due to negative earnings. Overall, the stock is high-risk, with substantial concerns over its financial sustainability.

Autonomix Medical, Inc. (AMIX) vs. S&P 500 (SPY)

Autonomix Medical, Inc. Business Overview & Revenue Model

Company DescriptionAutonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.
How the Company Makes MoneyAutonomix Medical, Inc. generates revenue through the sale of its medical devices and software solutions to hospitals, clinics, and healthcare professionals. Key revenue streams include one-time sales of its proprietary hardware, subscription-based licensing for its software platforms, and service agreements for ongoing maintenance and support. The company also engages in strategic partnerships with healthcare providers and technology firms to expand its reach and enhance its product offerings. Additionally, AMIX may earn revenue from research and development collaborations and intellectual property licensing agreements.

Autonomix Medical, Inc. Financial Statement Overview

Summary
Autonomix Medical, Inc. is struggling to generate revenue, which impacts its overall financial health. The company’s reliance on financing activities highlights potential vulnerabilities in sustaining operations without generating revenue. While the low debt levels are a positive aspect, the inability to generate positive cash flow or revenue presents significant risks that need addressing for future sustainability.
Income Statement
30
Negative
Autonomix Medical, Inc. is facing significant challenges with its income statement. The company reports zero total revenue across all periods, leading to negative gross profit, EBIT, and net income. The lack of revenue generation reflects a critical concern for the company's growth prospects and profitability.
Balance Sheet
45
Neutral
The balance sheet shows a reasonable equity position with a debt-to-equity ratio indicating low leverage, which is positive. However, the equity ratio has declined over the periods, suggesting an increase in liabilities relative to assets. The company appears to maintain a low level of debt, which mitigates risk, but there is little improvement in asset growth.
Cash Flow
40
Negative
Cash flow analysis reveals negative free cash flow and operating cash flow, indicative of operational challenges. The company is heavily reliant on financing activities to sustain operations, which could pose risks if external funding becomes less accessible. Although capital expenditure is minimal, the negative free cash flow suggests a need for strategic adjustments.
Breakdown
TTMMar 2024Mar 2023Mar 2022
Income StatementTotal Revenue
0.000.000.000.00
Gross Profit
-89.00K-81.00K0.000.00
EBIT
-10.75M-7.47M-1.99M-13.59M
EBITDA
-13.27M-15.27M0.00752.45K
Net Income Common Stockholders
-13.63M-15.43M-1.99M-13.33M
Balance SheetCash, Cash Equivalents and Short-Term Investments
11.82M8.61M864.62K2.04M
Total Assets
11.95M9.41M864.62K2.05M
Total Debt
1.13M1.00M0.000.00
Net Debt
-10.69M-7.61M-864.62K-2.04M
Total Liabilities
2.25M1.78M220.59K93.24K
Stockholders Equity
9.71M7.63M644.03K1.96M
Cash FlowFree Cash Flow
-8.06M-6.67M-1.85M-387.31K
Operating Cash Flow
-8.04M-6.65M-1.85M-387.31K
Investing Cash Flow
-29.00K-19.00K0.000.00
Financing Cash Flow
18.65M14.41M675.00K2.43M

Autonomix Medical, Inc. Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1.73
Price Trends
50DMA
2.53
Negative
100DMA
4.16
Negative
200DMA
9.87
Negative
Market Momentum
MACD
-0.24
Positive
RSI
32.84
Neutral
STOCH
8.85
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AMIX, the sentiment is Negative. The current price of 1.73 is below the 20-day moving average (MA) of 2.07, below the 50-day MA of 2.53, and below the 200-day MA of 9.87, indicating a bearish trend. The MACD of -0.24 indicates Positive momentum. The RSI at 32.84 is Neutral, neither overbought nor oversold. The STOCH value of 8.85 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AMIX.

Autonomix Medical, Inc. Risk Analysis

Autonomix Medical, Inc. disclosed 50 risk factors in its most recent earnings report. Autonomix Medical, Inc. reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Autonomix Medical, Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
73
Outperform
$177.44B77.3915.62%17.24%27.76%
70
Outperform
$2.26B66.6019.39%82.74%
69
Neutral
$4.74B91.138.48%28.49%
54
Neutral
$4.10B-18.87-17.06%5.92%25.76%-79.79%
51
Neutral
$869.61M55.81-5.16%-2.64%-193.31%
46
Neutral
$73.29M-51.63%11.26%-14.21%
37
Underperform
$4.26M-662.74%-10.29%
* General Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AMIX
Autonomix Medical, Inc.
1.74
-53.26
-96.84%
EDAP
EDAP TMS
1.87
-5.90
-75.93%
ISRG
Intuitive Surgical
507.05
123.63
32.24%
STAA
Staar Surgical
17.60
-21.47
-54.95%
INSP
Inspire Medical Systems
159.56
-50.63
-24.09%
TMDX
TransMedics Group
73.11
-2.24
-2.97%

Autonomix Medical, Inc. Corporate Events

Business Operations and StrategyRegulatory Filings and Compliance
Autonomix Medical CEO Engages in Investor Series
Neutral
Jan 22, 2025

On January 22, 2025, Autonomix Medical, Inc.’s CEO, Brad Hauser, participated in the Virtual Investor Closing Bell Series. The event was webcast live, with a replay available for 90 days, and marked a significant engagement with investors, offering insights into the company’s positioning and expectations. The conference presentation included forward-looking statements highlighting risks and uncertainties, emphasizing the need for stakeholders to review cautionary statements and disclosures filed with the SEC.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.